Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
This study will evaluate the safety and immunogenicity of VAX161B [STF2.HA5 H5N1], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
|Official Title:||Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years|
- Safety [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Assess safety, reactogenicity and tolerability. Symptoms will be collected from the memory aid and from the information collected at the clinic visits. All symptoms will be graded according to severity. Response to vaccine will be categorized as local (arm pain, redness, bruising, etc.) or systemic (headache, muscle aches, fatigue, etc.) symptoms. Laboratory tests such as CRP, WBC, LFTs and cytokines collected before and after vaccination will also be analyzed. We will compare the types and severity of symptoms and laboratory results based on vaccine dose.
- Immunogenicity [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]To assess serum immune response, sera collected at Days 0, 21, 42 and 180 will be analyzed for HAI, MN, serum IgG anti-HA and serum IgG anti-flagellin by Elisa. The geometric mean, seroconversion and seroprotection rates will be determined.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
Biological: VAX161 [STF2.HA5 H5N1]
dose escalating, 2 intramuscular doses given 21 days apart
The purpose of this study is to test an investigational vaccine known as "VAX161B". VAX161B is a vaccine for the influenza A virus subtype H5N1 avian influenza virus (bird flu). In this study, the subject will receive the VAX161B vaccine at one of five doses to see which does might be the best. VaxInnate want to find out how safe these vaccines are and how well they are tolerated by people who receive them. To measure how effective each type of vaccine is, VaxInnate will test the ability of the body to develop an immune response, which means how well the body recognizes and defends itself against the influenza virus.
|Contact: Cheryl Knipefirstname.lastname@example.org|
|United States, Florida|
|Miami Research Associates||Recruiting|
|Miami, Florida, United States, 33143|
|Contact: Marlene Piloto 305-279-0015 ext 4211|
|Principal Investigator: Eric Sheldon, MD|
|United States, Kansas|
|Johnson County Clin-Trials||Recruiting|
|Lenexa, Kansas, United States, 66219|
|Contact: Chris Rinehart 913-825-4408|
|Principal Investigator: Casey Johnson, DO|
|Principal Investigator:||Eric Sheldon, MD||Miami Research Associates|
|Principal Investigator:||Casey Johnson, DO||Johnson County Clin-Trials|